NYLI Balanced Investor Class holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
NYLI Balanced Investor Class MBINX
- NAV / 1-Day Return 33.15 / −0.24 %
- Total Assets 447.7M
-
Adj. Expense Ratio
1.330%
- Expense Ratio 1.320%
- Distribution Fee Level High
- Share Class Type Front Load
- Category Moderate Allocation
- Investment Style Large Value
- Credit Quality / Interest Rate Sensitivity Medium/Limited
- Status Open
- TTM Yield 1.66%
- Turnover 201%
USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 12:11 AM GMT+0
Morningstar’s Analysis MBINX
Will MBINX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 28.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
United States Treasury Notes 3.75% | 4.41 | 20M | Government |
iShares Intermediate Govt/Crdt Bd ETF | 3.79 | 17M | — |
Vanguard Intmdt-Term Trs ETF | 3.64 | 16M | — |
Alphabet Inc Class C | 3.31 | 15M | Communication Services |
United States Treasury Notes 4.125% | 3.20 | 14M | Government |
United States Treasury Notes 3.875% | 2.36 | 11M | Government |
United States Treasury Notes 3.875% | 2.20 | 10M | Government |
JPMorgan Chase & Co | 2.15 | 10M | Financial Services |
Merck & Co Inc | 1.60 | 7M | Healthcare |
Johnson & Johnson | 1.58 | 7M | Healthcare |